Excellent post by Masshysteria on ihub. Posting it
Post# of 154001
(Total Views: 834)
Posted On: 07/20/2021 9:53:19 PM
Excellent post by Masshysteria on ihub. Posting it here because it’s informative about the 13d group, and it will likely be deleted by ihub mods, aka the hedge fund short and distort team.
“The swordsman - You don't understand or perhaps are not aware of the circumstances around ECOR and why it was and is an absolute horror show of an investment. This factually sits on Errico and the rest of the founding and leadership team.
Financials:
Company way way overpriced with last two rounds of investment converting at around $10+ per share
IPO price offered to the investors at around $15 per share
The stock spent about a few hours above the offering price and immediately started to sink
All early (pre IPO investors were locked/restricted in share transaction activity for about 1 year (could be off but not by much)
At the time restriction was lifted the shares were worth less than 20% of the original investment
Here's the kicker - when selling the investment opportunity to investors, the sales projections were listed as $42MM for 2018, $142MM for 2019 and $280MM for 2020. You can do your own research but I can tell you that they are just getting to $12MM +/- in sales for 2021.... Yes - it was supposed to be $280MM last year and the numbers are just creeping past $12M. Brilliant.
So yes - nothing about this investment or the people associated with it is anything to highlight as a success or a target of association. At ANY level and any aspect of the business throughout its lifecycle to the present.
MOA and Therapeutic Modality
One more very important note.
To compare the development, testing and regulatory approval of a non invasive medical device designed to address pain management (no disrespect to pain or migraines which are devastating to have) to the process of developing testing and approving a biologic that targets viral entry and immune response/modulation on the cutting edge of science and current knowledge is absurd and a non starter.
The ECOR device, though innovative, is an external version of an implantable product whereby the science behind contact based vagus nerve stimulation was well understood over a very long period. While developing an innovative way to transmit elect stimulation impulses through the skin required some creativity and engineering prowess, it is just that and incomparable to the work going on to develop CCR5 based therapeutics.
There's so much more to say about the subject as well as the magnificent 13 but that is not the topic. Let's just not confuse ElectroCore with anything positive and at any level.”
“The swordsman - You don't understand or perhaps are not aware of the circumstances around ECOR and why it was and is an absolute horror show of an investment. This factually sits on Errico and the rest of the founding and leadership team.
Financials:
Company way way overpriced with last two rounds of investment converting at around $10+ per share
IPO price offered to the investors at around $15 per share
The stock spent about a few hours above the offering price and immediately started to sink
All early (pre IPO investors were locked/restricted in share transaction activity for about 1 year (could be off but not by much)
At the time restriction was lifted the shares were worth less than 20% of the original investment
Here's the kicker - when selling the investment opportunity to investors, the sales projections were listed as $42MM for 2018, $142MM for 2019 and $280MM for 2020. You can do your own research but I can tell you that they are just getting to $12MM +/- in sales for 2021.... Yes - it was supposed to be $280MM last year and the numbers are just creeping past $12M. Brilliant.
So yes - nothing about this investment or the people associated with it is anything to highlight as a success or a target of association. At ANY level and any aspect of the business throughout its lifecycle to the present.
MOA and Therapeutic Modality
One more very important note.
To compare the development, testing and regulatory approval of a non invasive medical device designed to address pain management (no disrespect to pain or migraines which are devastating to have) to the process of developing testing and approving a biologic that targets viral entry and immune response/modulation on the cutting edge of science and current knowledge is absurd and a non starter.
The ECOR device, though innovative, is an external version of an implantable product whereby the science behind contact based vagus nerve stimulation was well understood over a very long period. While developing an innovative way to transmit elect stimulation impulses through the skin required some creativity and engineering prowess, it is just that and incomparable to the work going on to develop CCR5 based therapeutics.
There's so much more to say about the subject as well as the magnificent 13 but that is not the topic. Let's just not confuse ElectroCore with anything positive and at any level.”
(17)
(0)